Predictive Value of Serum Anti-endometrial Antibodies in Implantation Rate for Patient With Endometriosis Undergoing Intracytoplasmic Sperm Injection Cycles
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- South Valley University
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- serum antiendometrial antibodies and implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles
Study Overview
Brief Summary
The aims of this study is to asses the predictive value of serum anti_endometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles.
Detailed Description
prospective cohort study of infertile patients ( with endometriosis & adenomyosis) who will undergo ICSI cycles at the assisted reproduction units,Obstetrics and Gynacology departments , South Valley University and Cairo University.
Initial evaluation: this will include:
- Detailed history and clinical examination.
- Ovarian reserve testing (serum AMH , basal serum FSH and basal AFC by US)
- Uterine cavity examination ( by trasvaginal 3-dimentional ultrasound or office hysteroscopy)
- routine investigations (Complete blood count, blood grouping , liver function tests , kidney function tests , prothrombin time , prothrombin concentration , serum bloog sugar)
- Evaluation of male factor (husbnad semen analysis)
-
Eligible women will undergo :
-
Transvaginal ultrasound for evaluation of endometriosis ( shape , size , unilateral or bilateral , unilocular or bilocular )
-
Perform laparscopy for confirmation of endometriosis using revised ASM classification for endometriosis
-
Measurement of serum anti_endometrial antibodies :
-
Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 15 Years to 35 Years (Child, Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients will be enrolled in this study if they fulfill the following criteria:
- •infertile patients (with endometriosis & adenomyosis ) who will undergo ICSI cycles
- •Age: 18-35 years.
- •Body mass index (BMI): ≤
- •primary or secondary infirtility. 5 duration of infertility less than 10 years
- •results of semen examination of patients' husbands will be within the World Health Organization (WHO) reference range.
Exclusion Criteria
- •Patients will not be eligible for this study if:
- •gynecological problem e.g. uterine polyp, hydrosalpinx will be excluded
- •Male factor: Abnormal sperm morphology;(globozoospermia and pin- point sperm) will be excluded 3 . congenital structural abnormalities of the reproductive tract, pelvic tuberculosis, ovarian tumour, hyperprolactinaemia, adrenal disease, thyroid disease or other endocrine disease,
Outcomes
Primary Outcomes
serum antiendometrial antibodies and implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles
Time Frame: baseline
assess the predictive value of serum antiendometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles
Secondary Outcomes
- serum antiendometrial antibodies in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles and egg quality retrieved(baseline)
Investigators
Mohammed Zain Al_a'bdeen
doctor
South Valley University